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ABBREVIATIONS 
Acetone crystallized mannitol, ACM; Bulk density, Db; Carr’s index, CI; 
Commercial lactose, CL; Commercial mannitol, CM; Cooling crystallized 
mannitol, CCM; Differential scanning calorimetry, DSC; Elongation ratio, 
ER; Ethanol crystallized mannitol, ECM; Fine particle dose, FPD; Fine 
particle fraction, FPF; Fourier transform infrared spectrometry, FT-IR; 
Geometric standard deviation, GSD; High performance liquid 
chromatography, HPLC; Impaction loss, IL; Mass median aerodynamic 
diameter, MMAD; Multi-Stage liquid impinge, MSLI; Next generation 
impactor, NGI; Particle size distribution, PSD; Salbutamol sulphate, SS; 
Scanning electron microscopy, SEM; Volume mean diameter, VMD. 
INTRODUCTION 
Inertial impaction methods performed by cascade impactors 
are considered as ‘the golden standard’ for testing of the 
inhalers, because they are capable to give information about 
the aerodynamic particle size, which is deeply related to 
particle deposition in the airways (1). With the previous 
studies demonstrating the variability of impactor efficiency 
with respect to drug type and dose, there is increased need 
to investigate the equivalence, or difference, of in vitro 
aerosolization performance using different cascade 
impactors. To best of our knowledge, there is no study to 
compare the drug deposition profiles in the case of carriers 
with considerably different morphologies using MSLI and 
NGI. To this end, carriers with an elongation ratio (ER) 
ranges from 1.6 (subrounded shape) up to 5.9 (needle 
shape) were selected (Figure 1), and drug inhalation 
behaviour was  analyzed using MSLI and NGI. 
METHODS 
Five different carriers were used in this study, i.e., 
commercial mannitol (CM), commercial lactose (CL), batch 
cooling crystallised mannitol (CCM), acetone crystallised 
mannitol (ACM) and ethanol crystallised mannitol (ECM) 
(2). Sieved 63-90 μm carrier particles were then 
characterised in terms of size (laser diffraction), shape 
(image analysis and SEM), flowability, density, and solid-
state (DSC and FT-IR). In vitro aerosolisation assessments 
were performed using both MSLI and NGI operating at 
flow rate of 92 L/min using Aerolizer
®
 inhaler device. 
Amounts of salbutamol sulphate (SS) drug were quantified 
using HPLC (Waters, USA). Fine particle fraction (FPF) 
was calculated as the percentage of fine particle dose (FPD≤ 
5 μm) to the recovered dose. Impaction loss (IL) was the per 
cent amounts of the drug deposited on the inhaler with 
mouthpiece adaptor plus throat to the recovered dose. 
RESULTS AND DISCUSSION 
The differences in carrier shape (Figure 1) resulted in 
variability of carrier powders in terms of particle size (e.g. 
VMD), flowability (e.g. CI), porosity, density and solid-
state form (Figure 1; Table 1).  
 
Figure 1. Volume mean diameter (VMD), elongation ratio (ER) 
and SEM images of CM, CL, CCM, ACM and ECM carriers. 
Carrier Db CI Porosity Polymorphic 
Product (g/cm
3
) (%) (%) form 
CL 0.55±0.00 17.0±2.6 64.0±0.1 α– 
CM 0.62±0.01 18.1±1.7 59.8±2.3 β– 
CCM 0.44±0.01 19.8±1.3 70.3±0.5 β– + δ– 
ACM 0.11±0.01 33.3±4.1 92.6±0.5 α– 
ECM 0.06±0.00 38.0±2.0 95.9±0.2 α– 
Table 1. Physical properties, i.e., bulk density (Db), Carr’s 
index (CI), porosity and polymorphic form, of different 
carrier products investigated.
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Figure 2. MMAD, GSD and FPF of SS generated by heterogeneous carriers, i.e., CM, CL, CCM, ACM and ECM as analyzed by 
MSLI and NGI. 
 
Carriers with higher ER demonstrated smaller bulk density, 
smaller tap density, higher porosity and poorer flow 
properties (Figure 1, Table 1). 
In comparison to MSLI, the obtained PSD data from NGI 
had bias towards smaller sizes (Figures not shown), due to 
possible bounce effects and inter-stage loses. NGI provided 
more accurate size fractionation than MSLI, because it 
resulted in steeper impaction-stage collection efficiency 
curves. In comparison to MSLI, NGI demonstrated 
generally smaller MMADs, smaller GSDs and smaller FPFs 
(Figure 2). 
Both impactors showed good agreement in terms of relative 
aerosolization behavior such as FPF (r
2
 = 0.8884) and IL (r
2
 
= 0.9745) (Figure 3). However, with increasing the 
elongation ratio of mannitol carrier particles, the absolute 
variations between GSDs (GSDs) and between FPDs 
(FPFs) increased whereas the absolute variations between 
MMADs (FPFs) decreased (Figure 4). 
 
Figure 3. FPF and IL of SS generated by heterogeneous 
carriers, i.e., CM, CL, CCM, ACM and ECM as analyzed by 
MSLI in relation to FPF and IL analyzed by NGI. 
CONCLUSION 
MSLI and NGI demonstrated agreement in terms of relative 
in vitro aerosolization performance of dry powder inhalers 
formulated with heterogeneous carriers having considerably 
different morphologies. However, formulators could expect 
some discrepancies when operating different impactors. For 
example, in comparison to NGI, MSLI demonstrated higher 
fine particle fractions. Despite the aerosolization 
performance has increased with the elongation ratio of 
carrier particles, there was a concurrent decrease in the 
absolute equivalency of the deposition data between MSLI 
and NGI in terms of GSD and FPF. 
 
Figure 4. Absoulte difference between MMAD, GSD and FPD 
in relation to ER of carrier product. 
REFERENCES 
1. De Boer, A.H.; Gjaltema, D.; Hagedoorn, P.; Frijnlink, 
H.W. Characterization of inhalation aerosols: a critical 
evaluation of cascade impactor analysis and laser   
diffraction technique. Int. J. Pharm. 249, 219–231 
(2002). 
2.Kaialy, W.; Alhalaweh, A.; Velaga, S.; Nokhodchi. A. 
Effect of carrier particle shape on dry powder inhaler 
performance. Int. J. Pharm. 421, 12–23 (2011). 
 
